Treatment with imatinib, a small molecule inhibitor of KIT, reversed the resistance phenotype completely, suggesting that imatinib is useful for treating KIT-overexpressing crizotinib-refractory NSCLC. This evidence concerns the gene KIT and non-small cell lung carcinoma.